subject inclusion question in replicate design for ANVISA [RSABE / ABEL]

posted by Shuanghe  – Spain, 2019-09-05 14:38 (540 d 00:08 ago) – Posting: # 20544
Views: 1,413

Hi Helmut,

» » […] the client's statistical consultant commented that only subjects who complete all 4 period (2T+2R) should be included, otherwise, they should be excluded even if they completed 3 period.
»
» IMHO, this doesn’t make sense. See the example in the vignette of replicateBE.

Thanks. That's my thought too so I insisted that the statistical section should be kept unchanged. Hopefully ANVISA will issue their own guideline soon...

All the best,
Shuanghe

Complete thread:

Activity
 Admin contact
21,356 posts in 4,458 threads, 1,493 registered users;
online 5 (0 registered, 5 guests [including 4 identified bots]).
Forum time: Friday 13:46 CET (Europe/Vienna)

Those who make no mistakes are making the biggest mistakes of all 
they are attempting nothing new.    Anthony de Mello

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5